Archives
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2018-07
-
Altogether the situations described above clearly impede the
2024-10-28

Altogether, the situations described above clearly impede the critical steps of drug discovery and development and the scientific process in general [14]. In conclusion, it is the opinion of these authors that many exciting lines of drug discovery (which includes those devoted to nAChR ligands) have
-
br Conclusions A large body of evidence
2024-10-28

Conclusions A large body of evidence indicates that oxidative stress is involved in the pathogenesis of NDDs. Hence, reducing oxidative stress or suppressing its downstream pathways may be beneficial for the treatment of these diseases, especially such chronic diseases as AD or glaucoma. Here we
-
However from our meta analysis emerge some strategic conside
2024-10-26

However, from our meta-analysis emerge some strategic considerations for the continued use of antiangiogenic drugs for glioblastoma patients: Conflict of interest Funding Introduction Angiogenesis is a physiological process involving the formation of new blood vessels from pre-existing blo
-
We next developed a system for staging severity Our guiding
2024-10-26

We next developed a system for staging severity. Our guiding principles were the following. Two types of information about the research participant are staged independently from each other: (1) grading disease severity using biomarkers and (2) grading the severity of cognitive impairment. Measures u
-
Tephrosia purpurea Linn pers Fabaceae a widely growing
2024-10-26

Tephrosia purpurea (Linn.) pers, (Fabaceae), a widely growing herbaceous perennial is reported to exhibit significant anti-hyperglycemic activity in animal models [7], [8], [9] as well as able to delay the development of diabetic complications [10], [11]. Recently, we have reported T. purpurea for i
-
In silico docking analysis performed in
2024-10-26

In silico docking analysis performed in the current study indicated that TCDD strongly binds to AhR-LBD. Moreover, the formation of the TCDD/AhR-LBD complex was confirmed experimentally with the use of EMSA. We found that 10nM TCDD after 2 hours of incubation not only bound to the AhR in the porcine
-
br Adiponectin receptors in colorectal cancer development
2024-10-26

Adiponectin receptors in colorectal cancer development APN receptors expressed in CRC tissue may mediate its effects on cell expansion and cell death (Byeon et al., 2010). It was observed that the expression of AdipoR1 and 2 is higher in CRC tissue than in counterpart healthy tissues (Williams et
-
br Acknowledgment br Introduction Vascular
2024-10-26

Acknowledgment Introduction Vascular smooth muscle cells (VSMC) exhibit the capacity to switch between a differentiated (contractile) and a dedifferentiated (synthetic) phenotype [1]. Synthetic VSMC express a lower amount of contractile proteins such as Smooth muscle 22α (sm22α) and α-Smooth m
-
Although ASD is considered one of the most heritable neurode
2024-10-26

Although ASD is considered one of the most heritable neurodevelopmental disorders (El-Fishawy & State, 2010; Geschwind, 2011) and majority of the research on ASD has focused on the genetics of the disorders (Autism Genome Project, C, 2007; Buxbaum & Hof, 2011), single causative gene anomalies accoun
-
Introduction Mammalian cells express the seven
2024-10-26

Introduction Mammalian N-acetyl D-galactosamine express the seven STAT family members STAT1, −2, −3, −4, −5A, −5B, and −6 [1], [2]. All STATs exert physiologically important roles as homo- and heterodimers [2], [3], [4]. Cytokines and growth factors activate STATs through the activation of kinases
-
The gene SRD A encodes the reductase
2024-10-26

The gene SRD5A2 encodes the 5-α-reductase enzyme, which converts testosterone into dihydrotestosterone. Although dihydrotestosterone levels are considerably lower than testosterone, dihydrotestosterone has a five-fold stronger binding capacity to the androgen receptor and, thereby, a considerably mo
-
In the current study we provide evidence that enhanced
2024-10-25

In the current study, we provide evidence that enhanced ATX activity correlates well with increased ATX protein concentration during cholestasis and pregnancy (Fig. 1). Hereby we have ruled out the possibility of ATX enzyme activation in these conditions, e.g. by circulating cholephiles. ATX clearan
-
The resolution cocrystal structure of ACL in complex
2024-10-25

The 2.10Å resolution cocrystal structure of ACL in complex with citrate indicates that the carboxyl (COH) groups of citrate forms a network of H-bonds with hydrophilic residues surrounding the ACL citrate binding domain (CBD) (A). The - carboxyl group forms a salt bridge with the guanidine moiety of
-
br Regulatory mechanisms of ASK activity
2024-10-25

Regulatory mechanisms of ASK1 activity The functions of ASK1 in disease ASK1 inhibitor As mentioned above, ASK1 plays a pivotal role in the pathogenesis of various diseases; hence, an ASK1 inhibitor has therapeutic potential. Although inhibitors of the ASK1 downstream kinases p38 and JNK ar
-
Aminoglutethimide first generation aromatase inhibitor has b
2024-10-25

Aminoglutethimide, first generation aromatase inhibitor, has been tried as an antiepileptic drug in combination with other standard drugs (Aguilar et al., 1961). Letrozole is a third generation reversible non-steroidal aromatase inhibitor, approved by US-FDA, for the treatment of postmenopausal wome
14069 records 69/938 page Previous Next First page 上5页 6667686970 下5页 Last page